NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has released a white paper titled “StereoCED™ – A Scalable Platform for CNS Drug Delivery,” available from the Scientific Resources section of nmtc1.com, highlighting the company’s approach to overcoming barriers in delivering therapeutics directly to the brain. The announcement comes as the company anticipates making the StereoCED™ platform available for research and investigational clinical studies by the end of its fiscal year.
The white paper addresses the growing demand for efficient and reproducible methods of central nervous system (CNS) drug delivery, driven by advances in cell and gene therapies, biologics, and other brain therapeutics. While convection-enhanced delivery (CED) has shown promise in bypassing the blood-brain barrier and achieving targeted drug distribution, current approaches may present challenges for broader commercial use, including lengthy procedure times and specialized workflows.
NeuroOne’s StereoCED™ platform is being designed to integrate with robotic stereotactic systems already common in neurosurgical operating rooms. Instead of requiring sequential infusions over many hours, the platform aims to support simultaneous, multi-trajectory intracranial drug delivery through a streamlined robotic workflow. This design could significantly reduce procedure time—potentially from 8 to 12 hours to a fraction of that—while enabling reproducible and scalable therapeutic delivery.
“Brain-delivered therapeutics are approaching an important inflection point,” said Dave Rosa, President and Chief Executive Officer of NeuroOne. “As these therapies move toward commercialization, certain intracranial infusion procedures lasting 8 to 12 hours may become a significant bottleneck to commercial adoption. We believe healthcare systems will need solutions that leverage established neurosurgical workflows, significantly reduce procedure time, and support scalable delivery across hospitals. StereoCED™ is being designed with those needs in mind, and we look forward to device availability for research and investigational clinical studies by fiscal year-end.”
The StereoCED™ platform is currently under development and has not received clearance or approval from the U.S. Food and Drug Administration for commercialization. NeuroOne is a medical technology company focused on improving surgical care for neurological disorders, with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for basivertebral nerve ablation and spinal cord stimulation programs.
As CNS therapies move closer to widespread use, the ability to deliver them efficiently and reproducibly will be critical. NeuroOne’s StereoCED™ platform, if successful, could help hospitals adopt these advanced treatments without requiring major workflow overhauls, potentially accelerating patient access to novel brain therapeutics.
